Intravenous thrombolysis in acute ischemic stroke with active cancer

Ki Woong Nam, Chi Kyung Kim, Tae Jung Kim, Sang Joon An, Kyungmi Oh, Sang Bae Ko, Byung Woo Yoon

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Ischemic stroke patients with active cancer are known to have poor clinical outcomes. However, the efficacy and safety of intravenous alteplase (IV t-PA) in this group are still unclear. In this study, we aimed to evaluate whether stroke patients with cancer had poor clinical outcomes after use of IV t-PA. We reviewed ischemic stroke patients with active cancer treated with isolated IV t-PA between April 2010 and March 2015 at three national university hospitals from the registry for ischemic stroke in Korea. The clinical outcomes of early neurological deterioration (END), hemorrhagic transformation, in-hospital mortality, 3-month modified Rankin scale (mRS), the National Institutes of Health Stroke Scale (NIHSS) discharge score, and duration of hospitalization were compared. We enrolled a total of 12 patients, and the cohort showed poor outcomes including 4 (33%) END events, 7 (58%) hemorrhagic transformations, 3 (25%) in-hospital mortality cases, and 7 (58%) poor mRS (3-6) scores. Additionally, the cryptogenic stroke group (n = 6) more frequently had high mRS scores (P = 0.043) as well as tendencies for frequent END events, hemorrhagic transformations, in-hospital mortality cases, and higher discharge NIHSS scores without statistical significance. In conclusion, ischemic stroke patients with active cancer, especially those with a cryptogenic mechanism, showed poor clinical outcomes after use of IV t-PA.

Original languageEnglish
Article number4635829
JournalBioMed Research International
Volume2017
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Stroke
Deterioration
Neoplasms
Hospital Mortality
Health
National Institutes of Health (U.S.)
Tissue Plasminogen Activator
Korea
Registries
Hospitalization
Safety

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Intravenous thrombolysis in acute ischemic stroke with active cancer. / Nam, Ki Woong; Kim, Chi Kyung; Kim, Tae Jung; An, Sang Joon; Oh, Kyungmi; Ko, Sang Bae; Yoon, Byung Woo.

In: BioMed Research International, Vol. 2017, 4635829, 01.01.2017.

Research output: Contribution to journalArticle

Nam, Ki Woong ; Kim, Chi Kyung ; Kim, Tae Jung ; An, Sang Joon ; Oh, Kyungmi ; Ko, Sang Bae ; Yoon, Byung Woo. / Intravenous thrombolysis in acute ischemic stroke with active cancer. In: BioMed Research International. 2017 ; Vol. 2017.
@article{56bc4ce749324087b5fb6ced4fd58686,
title = "Intravenous thrombolysis in acute ischemic stroke with active cancer",
abstract = "Ischemic stroke patients with active cancer are known to have poor clinical outcomes. However, the efficacy and safety of intravenous alteplase (IV t-PA) in this group are still unclear. In this study, we aimed to evaluate whether stroke patients with cancer had poor clinical outcomes after use of IV t-PA. We reviewed ischemic stroke patients with active cancer treated with isolated IV t-PA between April 2010 and March 2015 at three national university hospitals from the registry for ischemic stroke in Korea. The clinical outcomes of early neurological deterioration (END), hemorrhagic transformation, in-hospital mortality, 3-month modified Rankin scale (mRS), the National Institutes of Health Stroke Scale (NIHSS) discharge score, and duration of hospitalization were compared. We enrolled a total of 12 patients, and the cohort showed poor outcomes including 4 (33{\%}) END events, 7 (58{\%}) hemorrhagic transformations, 3 (25{\%}) in-hospital mortality cases, and 7 (58{\%}) poor mRS (3-6) scores. Additionally, the cryptogenic stroke group (n = 6) more frequently had high mRS scores (P = 0.043) as well as tendencies for frequent END events, hemorrhagic transformations, in-hospital mortality cases, and higher discharge NIHSS scores without statistical significance. In conclusion, ischemic stroke patients with active cancer, especially those with a cryptogenic mechanism, showed poor clinical outcomes after use of IV t-PA.",
author = "Nam, {Ki Woong} and Kim, {Chi Kyung} and Kim, {Tae Jung} and An, {Sang Joon} and Kyungmi Oh and Ko, {Sang Bae} and Yoon, {Byung Woo}",
year = "2017",
month = "1",
day = "1",
doi = "10.1155/2017/4635829",
language = "English",
volume = "2017",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Intravenous thrombolysis in acute ischemic stroke with active cancer

AU - Nam, Ki Woong

AU - Kim, Chi Kyung

AU - Kim, Tae Jung

AU - An, Sang Joon

AU - Oh, Kyungmi

AU - Ko, Sang Bae

AU - Yoon, Byung Woo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Ischemic stroke patients with active cancer are known to have poor clinical outcomes. However, the efficacy and safety of intravenous alteplase (IV t-PA) in this group are still unclear. In this study, we aimed to evaluate whether stroke patients with cancer had poor clinical outcomes after use of IV t-PA. We reviewed ischemic stroke patients with active cancer treated with isolated IV t-PA between April 2010 and March 2015 at three national university hospitals from the registry for ischemic stroke in Korea. The clinical outcomes of early neurological deterioration (END), hemorrhagic transformation, in-hospital mortality, 3-month modified Rankin scale (mRS), the National Institutes of Health Stroke Scale (NIHSS) discharge score, and duration of hospitalization were compared. We enrolled a total of 12 patients, and the cohort showed poor outcomes including 4 (33%) END events, 7 (58%) hemorrhagic transformations, 3 (25%) in-hospital mortality cases, and 7 (58%) poor mRS (3-6) scores. Additionally, the cryptogenic stroke group (n = 6) more frequently had high mRS scores (P = 0.043) as well as tendencies for frequent END events, hemorrhagic transformations, in-hospital mortality cases, and higher discharge NIHSS scores without statistical significance. In conclusion, ischemic stroke patients with active cancer, especially those with a cryptogenic mechanism, showed poor clinical outcomes after use of IV t-PA.

AB - Ischemic stroke patients with active cancer are known to have poor clinical outcomes. However, the efficacy and safety of intravenous alteplase (IV t-PA) in this group are still unclear. In this study, we aimed to evaluate whether stroke patients with cancer had poor clinical outcomes after use of IV t-PA. We reviewed ischemic stroke patients with active cancer treated with isolated IV t-PA between April 2010 and March 2015 at three national university hospitals from the registry for ischemic stroke in Korea. The clinical outcomes of early neurological deterioration (END), hemorrhagic transformation, in-hospital mortality, 3-month modified Rankin scale (mRS), the National Institutes of Health Stroke Scale (NIHSS) discharge score, and duration of hospitalization were compared. We enrolled a total of 12 patients, and the cohort showed poor outcomes including 4 (33%) END events, 7 (58%) hemorrhagic transformations, 3 (25%) in-hospital mortality cases, and 7 (58%) poor mRS (3-6) scores. Additionally, the cryptogenic stroke group (n = 6) more frequently had high mRS scores (P = 0.043) as well as tendencies for frequent END events, hemorrhagic transformations, in-hospital mortality cases, and higher discharge NIHSS scores without statistical significance. In conclusion, ischemic stroke patients with active cancer, especially those with a cryptogenic mechanism, showed poor clinical outcomes after use of IV t-PA.

UR - http://www.scopus.com/inward/record.url?scp=85021685395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021685395&partnerID=8YFLogxK

U2 - 10.1155/2017/4635829

DO - 10.1155/2017/4635829

M3 - Article

C2 - 28660209

AN - SCOPUS:85021685395

VL - 2017

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 4635829

ER -